Indaptus Therapeutics, Inc. (INDP)
| Market Cap | 151.90M +2,044.9% |
| Revenue (ttm) | n/a |
| Net Income | -15.42M |
| EPS | -0.47 |
| Shares Out | 133.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,084 |
| Open | 1.160 |
| Previous Close | 1.160 |
| Day's Range | 1.100 - 1.185 |
| 52-Week Range | 0.920 - 8.570 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About INDP
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and ... [Read more]
Financial Performance
Financial StatementsNews
Indaptus Therapeutics files to sell 59M shares of common stock for holders
17:02 EDT Indaptus Therapeutics (INDP) files to sell 59M shares of common stock for holders
Indaptus Therapeutics Registration statement: Registration filing
Indaptus Therapeutics filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced finan...
Indaptus Therapeutics Quarterly report: Q2 2026
Indaptus Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Indaptus Therapeutics Earnings release: Q2 2026
Indaptus Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Indaptus Therapeutics Proxy statement: Proxy filing
Indaptus Therapeutics filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
Indaptus Therapeutics files to sell 18.86M shares of common stock for holders
17:23 EDT Indaptus Therapeutics (INDP) files to sell 18.86M shares of common stock for holders
Indaptus Therapeutics Registration statement: Registration filing
Indaptus Therapeutics filed a registration statement on June 26, 2026, providing details about a securities offering with the SEC.
Indaptus Therapeutics Proxy statement: Proxy filing
Indaptus Therapeutics filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their sha...
Indaptus Therapeutics Quarterly report: Q1 2026
Indaptus Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Indaptus Therapeutics Earnings release: Q1 2026
Indaptus Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the f...
Indaptus Therapeutics Annual report: Q4 2025
Indaptus Therapeutics has published its Q4 2025 annual report on March 17, 2026.
Indaptus Therapeutics Proxy statement: Proxy filing
Indaptus Therapeutics filed a proxy statement on February 12, 2026, providing details for shareholder voting and corporate governance matters.
Indaptus Therapeutics Proxy statement: Proxy filing
Indaptus Therapeutics filed a proxy statement on January 21, 2026, providing details for shareholder voting and corporate governance matters.
Indaptus Therapeutics Proxy statement: Proxy filing
Indaptus Therapeutics filed a proxy statement on January 8, 2026, providing details for shareholder voting and corporate governance matters.
Indaptus Therapeutics enters $6M securities purchase agreement with David Lazar
Indaptus Therapeutics (INDP) entered into a $6M securities purchase agreement with investor, David Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been ...
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics reports Q3 EPS ($2.98) vs ($9.04) last year
Jeffrey Meckler, Indaptus Therapeutics (INDP)’ Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and t...
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics Quarterly report: Q3 2025
Indaptus Therapeutics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Indaptus Therapeutics Earnings release: Q3 2025
Indaptus Therapeutics released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
Indaptus Therapeutics provides update on INDP-D101 clinical trial
Indaptus Therapeutics (INDP) announced recent updates for the ongoing INDP-D101 clinical trial. “We currently have completed the monotherapy portion of our trial and have initiated seven patients in o...